
Obinutuzumab produced complete proteinuria remission in 36.1% of primary membranous nephropathy patients at 2 years vs 5.7% with tacrolimus.
Well-defined studies are crucial to effective process development.
In this interview with BioPharm International, James Blackwell, president of The Windshire Group, LLC, discusses stumbling blocks to process development; strategies for developing, scaling up, and scaling out bioprocesses; and challenges when working across multiple sites.






